株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性胆汁性肝硬変(PBC) : パイプライン分析

Primary Biliary Cirrhosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 200481
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.95円で換算しております。
Back to Top
原発性胆汁性肝硬変(PBC) : パイプライン分析 Primary Biliary Cirrhosis - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 95 Pages
概要

原発性胆汁性肝硬変(PCB)は肝臓の慢性疾患で、自己免疫性があるとされ、進行性の胆汁うっ帯や、時には末期肝疾患にまで進行することがあります。PBCの患者は女性がほとんどで、また50〜60歳代で発症するケースが最も多くなっています。

当レポートでは、世界各国での原発性胆汁性肝硬変(以下PBC)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

原発性胆汁性肝硬変(PBC)の概要

治療薬の開発

  • PBC向けパイプライン製品:概要
  • PBC向けパイプライン製品:比較分析

各企業で開発中のPBC治療薬

大学/研究機関で研究中のPBC治療薬

パイプライン製品の概略

  • 最終段階の製品
  • 治験段階の製品
  • 初期段階の製品

PBC治療薬:開発中の製品の一覧(企業別)

PBC治療薬の開発に従事している企業

  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Intercept Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.

原発性胆汁性肝硬変(PBC):治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • A-4250
  • budesonide
  • FFP-104
  • GSK-2330672
  • MBX-8025
  • NGM-282
  • obeticholic acid
  • RhuDex
  • Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis
  • ustekinumab
  • VBY-825

PBC治療薬:最新の薬剤プロファイル

PBC関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8964IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2017, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Phase 0 stages are 1, 1, 9, 5 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Biliary Cirrhosis - Overview
  • Primary Biliary Cirrhosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Primary Biliary Cirrhosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
    • Albireo Pharma Inc
    • Arena Pharmaceuticals Inc
    • CymaBay Therapeutics Inc
    • Eisai Co Ltd
    • Enanta Pharmaceuticals Inc
    • Genextra Spa
    • Genfit SA
    • GenKyoTex SA
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • MediGene AG
    • NGM Biopharmaceuticals Inc
    • Novartis AG
    • Retrophin Inc
    • Shire Plc
    • Virobay Inc
  • Primary Biliary Cirrhosis - Drug Profiles
    • A-4250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-6011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDP-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elafibranor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etrasimod arginine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FFP-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GKT-831 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-9674 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2330672 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJN-452 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • maralixibat chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RhuDex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seladelpar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ursodiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Biliary Cirrhosis - Dormant Projects
  • Primary Biliary Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
      • Oct 20, 2016: CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting
      • Oct 20, 2016: CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines Designation for the Treatment of Primary Biliary Cholangitis
      • Oct 05, 2016: CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
      • Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC
      • May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
      • May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
      • May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
      • Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
      • Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC
      • Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016
      • Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody
      • Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
      • Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015
      • Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Genextra Spa, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by MediGene AG, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Shire Plc, H1 2017
  • Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2017
  • Primary Biliary Cirrhosis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top